Several CTAgs, including the melanoma-associated antigen family, synovial sarcoma X antigens, and the immunogenic tumor antigen NY-ESO-1, have been identified as candidates for adaptive immunotherapies and cancer vaccines [145,146]. This evidence concerns the gene PSMB5 and neoplasm.